Vanishing platelets: Rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction

Nasir Rahman, Fahim H. Jafary

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Glycoprotein IIb/IIIa inhibitors are established treatment for patients who develop acute coronary syndromes. Thrombocytopenia is known to occur following the administration of various drugs, including heparin and glycoprotein IIb/IIIa inhibitors. In the case of glycoprotein IIb/IIIa inhibitors, the mechanism is thought to be drug-dependent antibodies. In most cases, the thrombocytopenia is mild or moderate in severity. Severe thrombocytopenia (platelet count, <50 × 109/L) is distinctly rare. Herein, we report a case of tirofiban-induced thrombocytopenia in which the overall platelet count dropped precipitously to <1 × 109/L within 12 hours of administration; recovery was relatively prolonged, possibly owing to concomitant renal insufficiency. The severity and the rapidity of onset emphasize the need to routinely check platelet counts early after tirofiban administration, in order to prevent sequelae.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalTexas Heart Institute Journal
Volume37
Issue number1
Publication statusPublished - 2010

Keywords

  • Acute coronary syndromes
  • Glycoprotein IIb/IIIa inhibitors
  • Percutaneous coronary intervention
  • Thrombocytopenia
  • Tirofiban

Fingerprint

Dive into the research topics of 'Vanishing platelets: Rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction'. Together they form a unique fingerprint.

Cite this